Participated · Equity · Feb 2024

Innerspace is an Innsbruck, Austria–based startup that provides software and virtual reality solutions for risk assessment of production processes and standardized cleanroom training for pharmaceutical personnel. Its offerings include a proprietary “Frame-by-Frame Risk Profiling” method and a standardized cleanroom simulator delivered in VR. The company applies psychological insights and innovative technologies to minimize human errors and reduce process risks in pharmaceutical manufacturing. Innerspace serves the pharmaceutical sector and is an official partner of the Parenteral Drug Association (PDA), helping develop and implement industry training courses. The company raised €5.7M to support product development and international expansion. Management plans to use the proceeds to expand its international market presence and further develop its Frame-by-Frame technology. Innerspace develops psychologically based training solutions for critical applications in the life‑science industry using its DeepTraining approach implemented in virtual reality. The platform prepares cleanroom operators for key moments of their work, allowing regular virtual practice to deepen behaviour patterns and understanding of production in critical areas. Innerspace already supplies numerous international pharmaceutical companies with its VR training products. Founded in 2017 and led by CEO Sebastian Scheler, the company is based in Wattens, Innsbruck, Austria. It raised over €1m in growth funding and plans to use the proceeds for global expansion and to double its team to approximately 50 employees.

Participated · Equity · Apr 2011

Indel Therapeutics is a Vancouver, Canada–based biopharmaceutical company focused on discovering novel antibiotic drugs to address antibiotic resistance. Its pipeline targets difficult-to-treat and hospital-acquired infections. The company closed a $1.4m second round of financing to fund its programs. Indel intends to use the proceeds to advance several antibiotic programs through animal proof-of-concept studies. In connection with the financing, Allan Collings, a co-founder and principal of ACM Advisors Ltd., joined the company’s board of directors. No revenue or user metrics are reported in the article.